Acute viral myocarditis by Dennert, Robert et al.
REVIEW
Acute viral myocarditis
Robert Dennert, Harry J. Crijns, and Stephane Heymans*
Department of Cardiology, CARIM, University Hospital Maastricht, The Netherlands
Received 9 January 2008; revised 5 June 2008; accepted 11 June 2008; online publish-ahead-of-print 9 July 2008
Acute myocarditis is one of the most challenging diagnosis in cardiology. At present, no diagnostic gold standard is
generally accepted, due to the insensitivity of traditional diagnostic tests. This leads to the need for new diagnostic
approaches, which resulted in the emergence of new molecular tests and a more detailed immunohistochemical analysis
of endomyocardial biopsies. Recent ﬁndings using these new diagnostic tests resulted in increased interest in inﬂamma-
tory cardiomyopathies and a better understanding of its pathophysiology, the recognition in overlap of virus-mediated
damage, inﬂammation, and autoimmune dysregulation. Novel results also pointed towards a broader spectrum of viral
genomes responsible for acute myocarditis, indicating a shift of enterovirus and adenovirus to parvovirus B19 and
human herpes virus 6. The present review proposes a general diagnostic approach, focuses on the viral aetiology
and associated autoimmune processes, and reviews treatment options for patients with acute viral myocarditis.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Myocarditis † Virus † Heart failure † Inﬂammation
Introduction
The term ‘myocarditis’ was ﬁrst introduced in the early 19th century
by Corvisart. However, at the beginning of the 20th century with the
recognitionofcoronaryarterydiseaseasanimportantcauseforheart
disease,thetermwaslargelydiscarded.
1Inattemptstostandardizethe
diagnosticcriteriafor myocarditis, the Dallasclassiﬁcation
2 wasintro-
duced in 1987. This classiﬁcation, however, has several pitfalls, being
susceptible to variation in pathological interpretation,
3 sampling
error,
4 and not considering the exact cause of pathological ﬁndings.
Therefore,itisnotanymoreusedasthegoldstandardforthediagnosis
ofviralorautoimmunemyocarditis,mainlyduetoitslackofadditional
immunostaining for inﬂammation and polymerase chain reaction
(PCR) for viral diagnosis. Recent efforts to redeﬁne viral and auto-
immune heart disease may therefore result in the so-called ‘death of
the Dallas Criteria’.
5 The diagnostic gold standard is endomyocardial
biopsy (EMB) with the histological Dallas criteria in conjunction with
the new tools of immunohistochemistry and viral PCR, according to
the 1995 WHO classiﬁcation of cardiomyopathies
6 (Table 1). The
useofthesenewdiagnostictoolshasevolvedinabetteridentiﬁcation
oftheaetiologyofmyocarditisandarenewedinterestinthemechan-
isms of the inﬂammatory process in the heart. These new insights of
the disease are mandatory to allow the development of novel
aetiology-directed treatment strategies.
Acute myocarditis is one of the most challenging diagnosis in
cardiology. Its entity is rarely recognized and its pathophysiology
defectively understood. The present review therefore proposes a
general diagnostic approach, focuses on the viral aetiology and
associated autoimmune process, and reviews treatment options
for patients with acute viral myocarditis.
Pathogenesis
Myocarditis is a disease with variable clinical presentation and pro-
gression.
7,8 In order to better understand its often unpredictable
progression, one has to address its underlying pathophysiological
process. Myocarditis is habitually viewed as a chronological
sequence of three pathologically distinct phases.
9 During the ﬁrst
phase, direct destruction of the cardiomyocytes occurs by virus-
mediated lysis,
10 causing degradation of cell structures, which in
turn facilitates entry of the virus into the cells with consequential
myocyte injury and cardiac dilatation.
11 This initial phase frequently
passes unnoticed since the initial damage is often prevented by the
innate immune response.
12 The second phase develops as a result
of immune dysregulation triggered by the initial cardiomyocyte
injury. The initial cellular and humoral immune responses may
improve the outcome during phase 1; conversely, they are respon-
sible for the harmful effect during phase 2. This is in part induced
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13 which is caused by mimicked epitopes
shared between the viral and cardiac antigens.
14 Finally, in the
third phase, a typical picture of dilated cardiomyopathy (DCM)
develops as a result of extensive myocardial injury.
9 Cross-reacting
antibodies with auto-antigens have been found in patients with
myocarditis
15 and are indicative of progression to DCM.
15 In
relation to cardiac auto-antibodies as predictors of progression
to DCM, the recent study by Caforio et al.
16 demonstrated that
cardiac auto-antibodies predict disease development in asympto-
matic relatives. Another mechanism for the development of auto-
immune responses is the virus-induced cardiomyocyte injury with
consequent release of intracellular cardiac proteins. The latter may
activate T-cells and associated cytokine mechanisms
17 evolving in
autoimmune myocarditis.
18 Initial myocardial injury by the virus,
and continuous low grade inﬂammation, induces enduring myo-
cardial damage and reparative ﬁbrosis. Inﬂammatory cells also pro-
duces matrix-degrading proteases,
19,20 all together leading to left
ventricular (LV) dilatation
21 and cardiac dysfunction
22 in stage 3
(Figure 1).
Two important observations in the progression of virus infec-
tion to heart failure remain unclear. First, patients with initial fulmi-
nant myocarditis that require intense haemodynamic support
rapidly recover within days and have a better long-term prognosis
when compared with patients with (sub)acute myocarditis, which
have a worse prognosis due to development of DCM.
7,12 The
precise reason for this difference is uncertain. One may postulate
that a fulminant inﬂammatory reaction, which is able to clear the
virus, may induce temporal stunning and dysfunction of the myo-
cardium. These patients probably do not enter the second phase
of viral-injury-mediated autoimmune responses, whereas patients
with virus persistence due to a (sub)acute, but insufﬁcient inﬂam-
matory reaction, are more prone to chronic autoimmune inﬂam-
mation and injury of the heart.
Secondly, it remains unclear why some patients develop myo-
carditis. The cardiotropic viruses causing myocarditis, including
adenovirus (ADV), enterovirus (EV), Epstein-Barr virus, human
herpes virus 6 (HHV6), parvovirus B19 (PVB19) and cytomegalo-
virus are common cough viruses. Although up to 90% of people
will catch one or more of these viruses in their life without
getting their heart affected, only a selected few develop clinical
symptoms. The exact incidence of myocarditis remains unclear,
partly due to the insensitivity of diagnostic tools used in previous
studies. This may cause an underestimation of its true incidence.
The prevalence of myocarditis has been found to be up to 42% in
cases of unexplained deaths in people aged 35 or younger.
23–25
Therefore, a certain genetic background, either or not related to
immune alterations, appears to be a requisite to develop clinical
symptoms of myocarditis and/or progression to DCM following
virus infection in the heart. A recent review, by Caforio and
Iliceto,
26 shows that in myocarditis/DCM, cardiac-speciﬁc and
disease-speciﬁc antibodies of IgG class are potential biomarkers
for identifying ‘at-risk’ relatives. As such, it has been shown that dys-
trophin mutations may facilitate myocarditis and cardiac failure
during coxsackievirus B3 infection, whereas dystrophin and/or sar-
coglycan disruption by viral proteases account for myocardial
injury.
14,27 Future research should therefore focus on the under-
standing of the underlying genetic susceptibility and related
immune responses that explain why some persons are susceptible
to develop clinical symptoms of myocarditis following viral infec-
tion, whereas others ‘spontaneously’ improve afterwards or pro-
gress to an ‘idiopathic’ DCM afterwards (Figure 2).
Diagnosis
The initial evaluation of acute myocarditis includes a detailed
history and a careful physical examination searching for any poten-
tial features that may provide clues to its aetiology. Additional
technical examination should include an electrocardiogram
(ECG), chest X-ray, blood studies, non-invasive imaging techniques,
and EMB.
Acute myocarditis has been associated with various infections
(Table 2). Viruses are the most important cause of acute myo-
carditis, especially in developed countries.
28–31 Based on sero-
logical studies, ADV and EV have long been considered the most
common cardiotropic viruses resulting in myocarditis,
32,33 but
recent studies using PCR for viral diagnosis in cardiac biopsies
pointed towards PVB19 and HHV6 as the most frequent patho-
gens in patients with acute myocarditis.
28,31,34,35
Clinical presentation
Symptoms of acute myocarditis vary, often starting with ﬂu-like
symptoms, either of the upper respiratory or gastrointestinal
Figure 1 Pathophysiological process of virus myocarditis.
Table 1 Deﬁnition and classiﬁcation of
cardiomyopathies according to the 1995 WHO/
International Society and Federation of Cardiology
Task Force
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy
Unclassiﬁed cardiomyopathies
R. Dennert et al. 2074tract, before any cardiac symptoms appear. Cardiac symptoms may
follow after a delay of days to weeks, including fatigue,
dyspnoea, palpitations, malaise, and atypical chest discomfort.
36
Further clinical signs may comprise sinus tachycardia, a diminished
ﬁrst heart sound, gallops, murmurs of mitral or tricuspid insufﬁ-
ciency, and, rarely but pathognomic, a pericardial friction rub.
Still, the clinical cardiac signs and symptoms may be vague in
many patients.
35 Therefore, this disease should be considered in
patients who present with rapidly progressive cardiomyopathy,
idiopathic ventricular arrhythmias, cardiovascular collapse, and/or
an ECG mimicking an acute myocardial infarction (MI) but with
normal coronary arteries.
37 Since the relation between clinical
ﬁndings and presence of acute myocarditis remains obscure, a
very speciﬁc and sensitive diagnostic procedure is warranted.
38
The differential diagnosis for acute viral myocarditis includes
other infectious causes for myocarditis (Table 2), acute MI, giant
cell myocarditis, eosinophilic myocarditis, peripartum cardiomyo-
pathy and cardiac sarcoidosis.
Viral serology
Traditional serological studies, peripheral viral cultures, have been
used to identify the most frequent pathogens for viral myocarditis
in the past. Unfortunately, these methods lack sensitivity and speci-
ﬁcity.
5 When seroconversion (low IgG, raised IgM, and IgA) occurs
at the time of the cardiac symptoms, it may suggest viral cardiac
manifestation. However, these assays do not prove direct presence
of virus infection in the heart due to the high background pre-
valence, and hence they can be helpful to identify the aetiology
in a selected patient group who do not undergo EMB for additional
PCR and immunohistochemical analysis of inﬂammation.
Biopsies
The current indication for EMB is ‘a strong reason to believe that
the results will have a meaningful effect on subsequent therapeutic
decisions’ according to the American College of Cardiology/
American Heart Association guidelines.
39,40 This guideline supports
the use of EMB for patients presenting with unexplained new-onset
heart failure ,2 weeks in duration associated with a normal-sized
or dilated left ventricle in addition to haemodynamic compromise.
The timeframe in obtaining EMBs remains controversial. A con-
servative approach where clinicians wait for a maximum of 2 days
before performing EMBs is justiﬁed. This is due to a high amount of
patients who recover spontaneously, as seen in up to 57% of the
cases.
7,8 However, in the case of persistent or increasing cardiac
dysfunction, urgent coronary angiography should be performed
and EMB taken without delay in the presence of non-signiﬁcant
coronary artery disease.
In contrast, a more invasive approach where EMBs are obtained
in all patients with suspected myocarditis could be justiﬁed taking
into account its high diagnostic sensitivity in the earliest stages of
myocarditis. In addition, aetiology-based therapy is more effective
when started early, before inﬂammation causes injury and the
remodelling progress has become irreversible. Obtaining EMBs at
presentation is valuable in understanding the potential role of
speciﬁc aetiological factor, such as speciﬁc viral agents, double
infections, high viral load and/or immunohistological inﬂammation.
New studies in which informed written consent is obtained from
the patient with his/her full understanding of performing EMBs at
presentation are required (Figure 3).
The EMB analysis should include routine light microscopy,
immunohistological techniques for inﬂammation, and PCR for virus
detection.
Biopsies: viral diagnosis
With the introduction of new molecular techniques, such as PCR
and in situ hybridization, many different viruses have been found to
be associated with myocarditis: especially a high prevalence of
Table 2 Infectious causes of myocarditis
Viral
Adenovirus, Arbovirus, Arenavirus, Coxsackie virus, Epstein–Barr
virus, Cytomegalovirus, Echovirus, Encephalomyocarditis virus,
Hepatitis B, Human Herpes virus 6, Human immunodeﬁciency
virus-1,InﬂuenzavirusB, Mumpsvirus,ParvovirusB19,Poliomyelitis
virus, Rabies, Respiratory syncytial virus, Rubella virus, Rubeola
virus, Vaccinia virus, Varicella virus, Variola virus
Bacterial
Brucellosis, Clostridia, Diphtheria, Francisella, Gonococcus,
Haemophilus, Legionella, Meningococcus, Mycobacterium,
Mycoplasma, Pneumococcus, Psittacosis, Salmonella,
Staphylococcus, Streptococcus, Tropheryma whippleii
Fungal
Actinomyces, Aspergillus, Blastomyces, Candida, Coccidioides,
Cryptococcus, Histoplasma, Nocardia, Sporothrix
Rickettsial
Rocky Mountain spotted fever, Q fever, Scrub typhus, Typhus
Spirochetal
Borrelia, Leptospira, Syphilis
Helminthic
Cysticercus, Echinococcus, Schistosoma, Toxocara, Trichinella
Protozoal
Entamoeba, Leishmania, Trypanosoma, Toxoplasmosis
Figure 2 Evolution of acute viral myocarditis. DCM, dilated
cardiomyopathy.
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28,31,34,35,41 (reviewed
in Table 3). Some but not all studies reveal a high prevalence of
PVB19 ranging from 15 to 60% and HHV6 ranging from 8 to
30% using PCR analyses in EMBs from patients with immunohisto-
logical myocarditis. They show similar virus prevalence in patients
with DCM compared with acute myocarditis, underscoring the
pathogenic process where viruses are the triggers for long-term
cardiac injury and dysfunction. The presence of PVB19 and
especially a dual infection of PVB19 and HHV6 are associated
with a worse prognosis in patients with acute myocarditis.
28,31
In conclusion, recent ﬁndings using these new diagnostic tests
point towards a broader spectrum of viral genomes responsible
for acute myocarditis, indicating a shift of EV and ADV to PVB19
and HHV6 as the most frequent viruses causing acute myocarditis.
Biopsies: histological evaluation
Histological evaluation of biopsies was initially done according to the
Dallas criteria.
2 The presence of an inﬂammatory inﬁltrate with or
without necrosis under light microscopy was required for the histo-
logical diagnosis of myocarditis. The absence of myocyte necrosis
and a sparser inﬂammatory inﬁltrate suggests borderline myocarditis.
However, several investigations have raised questions whether the
Dallas criteria are sensitive enough to identify viral cardiomyopathy.
In addition, various studies have shown a rather large variability of
39% among pathologists examining the same cardiac tissue
samples.
7 Biopsies obtained from different parts of the right ventricle
may or may not show focal inﬁltrates (spatial variability), and biopsies
obtainedatdifferenttimepointsdocumentintermittentinﬂammatory
inﬁltrates(temporalvariability).
4InEMBscontainingPCR-provenviral
pathogens, the Dallas criteria were absent in 50% of thespecimens.
41
Forthisreason,thesolitaryuseoftheDallascriteriatodiagnosemyo-
carditisispoor,sinceitissusceptibletosamplingerrorandvariationin
observer expertise, and it does not consider viral persistence and
auto-immune regulation.
5
To address the shortcomings, additional immunohistological
and quantitative evaluation of the EMB is required. Immunohisto-
chemical techniques allow quantiﬁcation, identiﬁcation, and differ-
entiation of inﬂammatory cells, focusing on T-lymphocytes.
42
Criteria for immunohistological diagnosis in the endomyocardial
biopsy of inﬂammatory cardiomyopathy is speciﬁed quantitatively
as  14 inﬁltrating leukocytes/mm
2, preferably T-lymphocytes or
activated T-cells. If foci of T-lymphocytes are present, active myo-
carditis can be diagnosed due to the nature of the inﬁltrate even
when the critical number of 14 leukocytes/mm
2 is not reached,
as has been deﬁned by the task force of the World Heart Federa-
tion’s Council on Cardiomyopathies.
43
Blood studies
Cardiac enzymes
Speciﬁc markers for acute myocarditis in routine blood studies are
lacking. In general, cardiac enzymes are elevated, but its reliability
to detect myocarditis has repeatedly been questioned.
44 Serum
levels of cardiac troponins are more sensitive in patients with
clinically suspected myocarditis than conventional determination
of creatine kinase levels and indicate myocyte injury.
45 Cardiac
troponin was mainly elevated in patients with acute, early-onset
myocarditis, whereas the absence of increased levels suggests
long-term presence of myocarditis. Unfortunately, the prognostic
value of cardiac troponin remains unclear.
Cardiac auto-antibodies
The pathophysiological role of auto-antibodies in cardiac injury
after acute viral infection is still under discussion.
13,46,47 Auto-
antibodies against contractile structures,
48–50 proteins involved
in energy metabolism/transfer,
51,52 ion channels and transpor-
ters,
53 and sarcolemmal receptors
54 have been identiﬁed in
myocarditis. Circulating cardiac auto-antibodies, in particular
antibodies against cardiac myosin heavy chain, may play a key
role as a clinical and pathogenetic marker and may also have
some prognostic value.
15,55 Indications for their role in the patho-
physiology of myocarditis are that: (i) various auto-antibodies can
produce inadequate inﬂammation in the heart and directly injure
cardiomyocytes
56; (ii) transfer of human lymphocytes from patients
with proven heart-reactive auto-antibodies into severe combined
immunodeﬁciency mice leads to autoantibody production, myo-
cardial inﬂammation, and impaired cardiac function
57; (iii) active
immunization with cardiac auto-antigens leads to anto-antibody
production, heart-speciﬁc inﬂammation, and cardiac dysfunc-
tion
48,58; and (iv) direct transfer of auto-antibodies against cTnI
and b-adrenoreceptor into rodents results in cardiac dilatation
and dysfunction.
59 Antibodies of the IgG class are cardiac and
Figure 3 Proposal of diagnostic approach for patients with sus-
pected myocarditis. Asterisk indicates that when informed
consent is obtained to perform endomyocardial biopsy at presen-
tation, the procedure is continued, if not proceed with the steps
as suggested in the ﬂowchart. CMR, cardiovascular magnetic
imaging; EMB, endomyocardial biopsy.
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Table 3 Prevalence of viruses using PCR in endomyocardial biopsies
Type of patients Number of
patients
Reference PVB19 HHV6 EV ADV EBV CMV No virus Comment
Dallas MC criteria 624 Bowles et al.
29 ND ND 85 (14%) 142 (23%) 3 (0.5%) 18 (3%) 385 (62%) No analyses for PVB19 was
done
DCM 149 ND ND 18 (8%) 12 (12%) 0 (0%) 0 (0%) 119 (80%) Parvovirus 6 in MC was ,1%
Immunohistochemical MC
criteria
36 Pankuweit
et al.
91
7 (19%) ND ND ND ND ND 19 (81%) Only analyses for PVB19
DCMi 13 3 (23%) ND ND ND ND ND 10 (77%)
Clinical MC 32 Mahrholdt
et al.
34
12 (38%) 6 (19%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 14 (43%)
With Dallas MC criteria 20 out of 32 12 (60%) 6 (30%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (10%)
PCR-proven viral MC 172 Kuhl et al.
31 63 (37%) 18 (11%) 56 (33%) 14 (8%) ND ND NA Dual infections in 21 patients
PPCM 26 Bultmann
et al.
92
4 (15%) 2 (8%) 0 (0%) 0 (0%) 1 (4%) 1 (4%) 18 (69%)
With immunohistochemical
inﬂammation
19 out of 26 4 (21%) 2 (11%) 0 (0%) 0 (0%) 1 (5%) 1 (5%) 11 (58%)
Idiopathic DCM 245 Kuhl et al.
28 126 (51%) 53 (22%) 23 (9%) 4 (2%) 5 (2%) 2 (,1%) 80 (33%) Dual infections in 45 patients
Dallas MC criteria 87 Mahrholdt
et al.
35
49 (56%) 16 (18%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 5 (6%)
Dallas MC criteria 120 Caforio et al.
61 3 (2.5%) ND 15 (12.5%) 6 (5%) 5 (4%) 3 (2.5%) 89 (74%) Mumps in three patients (2.5%),
HHV1 in one (1%), and
hepatitis C in two (2%). Dual
infections in ﬁve patients
DCM, dilated cardiomyopathy; DCMi, dilated cardiomyopathy with inﬂammation; PPCM, peripartum cardiomyopathy; PVB19, parvovirus B19; EV, enterovirus; HHV6, human herpes virus 6; ADV, andenovirus; EBV, Ebstein–Barr virus; CBV
Coxacksie B virus; CMV, cytomegalovirus; MC, myocarditis; HHV1, human herpes virus 1; ND, not determined; NA, not applicable.
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7disease speciﬁc for myocarditis, can be used to determine an auto-
immune pathogenesis,
15,60 and are present in up to 50% of patients
with active to borderline biopsy-proven myocarditis.
61 Further
studies are required to study whether this subgroup of patients
might beneﬁt from immunosuppressive and/or immunomodulation
therapy.
59,61
Electrocardiogram
Patients with acute myocarditis frequently have abnormal ECGs
ranging from conduction delays to ECGs mimicking acute MI or
acute pericarditis.
37,62 Its sensitivity is estimated at 47%, but its
speciﬁcity remains unknown.
63 Acute myocarditis may also result
in ‘idiopathic’ atrial or ventricular arrhythmias, PQ-segment
depression, and diffusely elevated ST-T-segments (Figure 4) which
evolve in ST-T-segment depression.
64
Natural history
The natural history of acute myocarditis varies from early death to
multisystem failure (fulminant myocarditis), ventricular arrhyth-
mias, complete recovery, and long-term evolution to DCM.
8
There are no large population-based, epidemiological studies
deﬁning the presenting symptoms of acute myocarditis, which is
partly due to the absence of sensitive non-invasive diagnostic
tests that are able to conﬁrm its diagnosis. Keeping in mind its dif-
ﬁcult diagnosis and often its asymptomatic course, D’Ambrosio
et al.
8 reviewed all current reports to describe the natural
history of histology-proven acute myocarditis. They report spon-
taneous improvement in 50–57% of histology-conﬁrmed cases
7
and a variable incidence to develop DCM in 14–52%,
65,66 with a
higher incidence of DCM in a subset of patients presenting with
congestive heart failure compared with patients with other types
of clinical presentation (arrhythmias and/or chest pain).
67 Long-
term prognosis was usually good with a 3–5-year survival
ranging from 56 to 83%, respectively.
68,69 Patients with acute fulmi-
nant myocarditis, once they survive the acute illness, had an excel-
lent long-term prognosis of 93% at 11 years, compared with 45%
of the patients presenting with acute non-fulminant myocarditis.
12
In patients with idiopathic CMP or a previous history of myocar-
ditis, Kuhl et al.
28 showed that viral persistence in the myocardium
is associated with progressive LV deterioration, whereas clearance
of the viral genomes resulted in a signiﬁcant improvement of LV
function. In patients with acute myocarditis, an initial decline with
a 1-year mortality rate of 20%
7,69 which gradually stabilizes after
3 years has been reported.
12 Therefore, we advise a follow-up of
at least 3 years after presentation or longer since myocarditis
may recur even many years after the initial episode (Figure 3).
Patients with cardiac deterioration or recurrent episodes of myo-
carditis during this time should receive adequate therapeutic and/
or diagnostic measures, whereas clinically stable patients should
be discharged from follow-up.
Imaging tools
Echocardiogram
The echocardiographic ﬁndings of (sub)acute myocarditis may
largely vary, showing marked LV dilation, normal LV thickness, and
decreased function. Systolic dysfunction, regional wall motion
abnormalities, and diastolic dysfunction all have been described.
70
However, many cases of myocarditis do not show abnormal LV
function,
71–73 thus limiting its utility for the diagnosis of myocarditis.
It can be useful in distinguishing fulminant myocarditis from subacute
myocarditis, as the former often presents with a non-dilated,
thickened and hypocontractile left ventricle. This is likely due to
the greater inﬂammatory response in fulminant myocarditis resulting
in interstitial oedema, ventricular wall thickening and loss of
ventricular contractility.
70 New echocardiographic modalities (such
as TDI strain) are emerging and hold promise in relation to the
detection of dysfunction in patients with standard transthoracic
echocardiography. Until these methods are validated in detecting
myocarditis, we advise to always perform cardiovascular magnetic
resonance (CMR) imaging in addition to echocardiography.
Nuclear imaging
Gallium scanning has been shown to be a useful diagnostic tool
for detecting chronic inﬂammation; nevertheless, due to its lack
of sensitivity (8%), its use has diminished over the course of
time.
74 Antimyosin antibody imaging has been described as
a screening method for myocarditis with a high sensitivity
(91–100%) and negative predictive value (93–100%) by detecting
localized or diffuse myocardial necrosis.
75 Unfortunately, due to its
limited availability, pronounced radiation exposure, and 48 h delay
in obtaining images, its use remained restricted.
Cardiovascular magnetic resonance
imaging
CMR imaging has emerged as the most important imaging tool in
the diagnostic procedure. Especially, gadolinium late enhancement
(LE) and T2-weighted image sequences (Figure 5) distinguish
between ischaemic and non-ischaemic cardiomyopathy. Patients
with ischaemic cardiomyopathy have subendocardial or transmural
enhancement compared with the non-ischaemic DCM group that
may have three distinct patterns, including the absence of enhance-
ment (59%), patchy or longitudinal striae of mid-wall enhancement
(28%), with a minority having myocardial enhancement indistin-
guishable from patients with ischaemic cardiomyopathy (13%).
76
LE distributions in MI patients show a smaller number of segmental
Figure 4 Electrocardiogram showing PQ-segment depression
and diffusely elevated ST-T-segments at presentation (A) and
evolution after 1 day (B).
R. Dennert et al. 2078vascular distributions in contrast to a more diffuse, nodular or patchy,
non-segmental vascular distribution in myocarditis patients.
77
Whereas increased LE indicates myocardial injury, T2-weighted
images mark interstitial oedema, which is an integral part of the
inﬂammatory response.
78 Thus, visual assessment of T2 images
relating the signal intensity of the myocardium to that of skeletal
muscle (if not affected) allows estimating global oedema and offers
a high accuracy to identify myocarditis, with a sensitivity of 100%
and speciﬁcity of 90%.
71
Therefore, combined CMR approach of T2-weighted imaging
and early and late gadolinium enhancement provides a high diag-
nostic accuracy and should become standard imaging in patients
with a suspicion of myocarditis.
71,79
Treatment
Patients with acute myocarditis should limit physical activity, as
exercise during active viral infection may increase viral replication
and shorten survival.
80 They should also receive standard
heart failure treatment including diuretics, b-blockers, angiotensin-
converting enzyme-inhibitors or angiotensin II receptor blockers.
Arrhythmias should be monitored and treated. Mechanical support
with intra-aortic balloon pump or LV assist device as a bridge to
recovery or heart transplantation may be necessary in severe
cases.
81 These measures are, however, intended for symptomatic
relief. To halt disease progression and possible evolution to DCM,
the underlying pathogenic mechanisms, e.g. virus infection or persist-
ence and autoimmune-mediated myocardial damage should be
addressed. The challenge of treating these primary mechanisms
requires detailed diagnosis of the pathogen and sufﬁcient knowledge
of the pathophysiology leading to heart failure (Figure 6).
Earlier trials for myocarditis lacked speciﬁc diagnosis of viral
presence and/or autoimmune diseases. The Myocarditis Treatment
Trial by Mason et al.
7 failed to show support for immunosuppressive
therapy in 111 patients with biopsy-proven myocarditis and
a depressed LV function. Immunosuppressive therapy on top
ofconventionaltherapydidnotsigniﬁcantlyimproveLVsystolicfunc-
tion or overall survival. This trial, however, had several pitfalls: treat-
ment was not blinded and the diagnosis of myocarditis was made
solely on the histological Dallas criteria. Immune suppression may
bebeneﬁcialinpatientswithsystemicdisease-relatedorautoimmune
myocarditis, whereas it may increase virus replication and worsen
myocardial injury in viral myocarditis. In another trial by McNamara
et al.
82 including 62 patients with myocarditis or recent onset idio-
pathic DCM, intravenous immune globulin did not signiﬁcantly
improve LV function or overall mortality when compared with the
placebo group. LV function improved signiﬁcantly in both groups
during a 12-month follow-up, indicating a favourable short-term
prognosis in this subset of patients. This trial also based its diagnosis
of myocarditis solely on the Dallas criteria. Both these trials failed to
show any evidence to support immunomodulatory therapy for
patients with myocarditis or recent-onset DCM. These ﬁndings
emphasize the importance of identifying the underlying aetiological
pathogenesis to ﬁnd a speciﬁc subgroup of patients who might
beneﬁt from immunomodulatory therapy. In a study of 102 patients
with idiopathic cardiomyopathy treated with immunosuppressive
therapy, improvement of LV function was only seen in patients with
evidenceofinﬂammation,theso-called‘reactive’patients.
83‘Reactive’
patients were those with ﬁbroblastic or lymphocytic inﬁltration or
immunoglobulin deposition on endomyocardial biopsy, a positive
galliumscan,oranelevatederythrocytesedimentationrate.Thenon-
reactive patient group did not improve in LV function despite treat-
ment with immunomodulatory therapy. A randomized, placebo-
controlled study
84 further conﬁrmed this concept, revealing a long-
term improvement in LVEF of 19% compared with 7% (P , 0.001)
with the short-term use of prednisone and azathioprine compared
with placebo in 84 patients with immunohistologically proven
chronic myocarditis. Post hoc analysis revealed a high prevalence of
Figure 5 Cardiovascular magnetic resonance image. Short-axis cardiac magnetic resonance imaging of a patient with acute myocarditis
(A) T2-weighted image, showing regional oedema of the lateral left ventricle predominantly subepicardial involvement (arrow). (B) Late
enhancement image, demonstrating high signal intensity in the epicardial region of the lateral wall of the left ventricle (arrow).
Acute viral myocarditis 2079virus persistence but absent anti-cardiac antibodies in the non-
responders,incontrasttoahighprevalenceofanti-cardiacantibodies
in the responders to immunosuppressive therapy.
85 The importance
of identifying a virological proﬁle has been further elaborated
86 in a
small phase II study including 22 patients with myocarditis or DCM
with virus persistence in the heart. Patients were treated with
interferon-b (Beneferon) 18 10
6 IU/week for 24 weeks, which
resulted in complete elimination of both enteroviral and adenoviral
genomes and haemodynamic improvement as shown by improve-
ment in LVEF. A prospective placebo-controlled randomized multi-
centre study, the Betaferon
w in Chronic Viral Cardiomyopathy
(BICC) trial, has been initiated since 2002.
87
Preventing direct viral damage using antiviral therapy is one
possible approach. Inhibition of viral proliferation by preventing
interaction of viruses with their cellular receptor and their con-
sequent signalling ampliﬁcation systems, such as the tyrosine kinase
p56lck, phosphatase CD45 and downstream ERK1/2, and the family
of cytokines,
88,89 is another approach. Therefore, additional research
is required to further understand the mechanisms of viral heart
disease and consequently identify new potential targets for therapy.
In summary, most trials suggest that immunomodulatory and/or
antiviral treatment may be beneﬁcial in cohorts of patients with a
very speciﬁc diagnosis and related aetiology. Thus, classiﬁcation of
the underlying mechanisms should lead to different therapeutic
approaches aimed to: (i) adequately target the speciﬁc aetiology
and (ii) to prevent treatment of an autoimmune disease by
global immunosuppressive treatment in patients with an infectious
disease.
90 Currently, evidence-based guidelines in favour of these
speciﬁc treatment options are lacking. Future clinical studies,
including immunosuppressive, immunomodulatory, and/or antiviral
treatment, according to the algorithm proposed in Figure 6 should
only be performed after obtaining informed consent from the patient
in speciﬁc reference centres.
Conclusion
Patients suspected of acute myocarditis should undergo a complete
cardiological work-up, including standard cardiological examination,
ECG, blood analyses with standard cardiac enzymes, and serum
tests for anti-heart auto-antibodies, imaging techniques (echocardio-
gram and especially CMR), and EMBs for both PCR and immuno-
histochemical analysis as suggested (Figure 3).
Myocarditis is a disease with a variable natural history. However,
due to the insensitivity of traditional diagnostic tests, its diagnosis
was difﬁcult in the past. The emergence of CMR as a valuable
diagnostic tool combined with new, more sensitive and speciﬁc,
molecular diagnostic tests in blood and EMB has led to renewed
interest in inﬂammatory cardiomyopathies and to the better under-
standing of their pathophysiology. The recognition in overlap of
virus-mediated damage, inﬂammation, and autoimmune dysregula-
tion in these patients, together with the combined effort of
clinicians, pathologists, and immunologists resulted in a better classi-
ﬁcation of the disease. Future randomized placebo-controlled trials
should be based upon aetiological diagnosis (viral vs. autoimmune
patients) and may provide novel treatment options and possibly a
better prognosis for these selected patients.
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